Free Trial

Portage Biotech (ALP) 10K Form and Latest SEC Filings 2026

Portage Biotech logo
$3.10 -0.14 (-4.32%)
As of 11/12/2026 04:00 PM Eastern

Latest Portage Biotech SEC Filings & Recent Activity

Portage Biotech (NASDAQ:ALP) has submitted 236+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Portage Biotech's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on November 6, 2026.

Form 4
Alpha Compute Corp Reports Ownership Change on Oct. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

20-F
Portage Biotech Files Annual Report on Aug. 5, 2026

The 20-F contains Portage Biotech's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Portage Biotech SEC Filing History

Browse Portage Biotech's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
11/06/2026 3:10 PM
Portage Biotech (1095435) Subject
JANE STREET GROUP, LLC (1595888) Filed by
Form SCHEDULE 13G/A
10/30/2026 3:05 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/13/2026 6:34 AM
Portage Biotech (1095435) Issuer
Villani Fiorenzo (1889272) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2026 10:13 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/05/2026 6:12 PM
Portage Biotech (1095435) Issuer
Mitin Yury (2088736) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/05/2026 6:13 PM
Portage Biotech (1095435) Issuer
Mitin Yury (2088736) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2026 8:09 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/23/2026 3:37 PM
Portage Biotech (1095435) Issuer
Villani Fiorenzo (1889272) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/22/2026 8:10 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2026 5:25 PM
Portage Biotech (1095435) Issuer
Villani Fiorenzo (1889272) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/14/2026 6:25 AM
Portage Biotech (1095435) Issuer
Kaiser Brittany (1918874) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/14/2026 6:27 AM
Portage Biotech (1095435) Issuer
Villani Fiorenzo (1889272) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/14/2026 5:35 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2026 7:39 PM
Portage Biotech (1095435) Issuer
Levitt Wesley Allen (1886953) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2026 3:10 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/03/2026 11:03 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2026 8:41 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/27/2026 1:09 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/20/2026 12:48 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/11/2026 2:41 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/05/2026 8:46 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/05/2026 8:48 PM
Portage Biotech (1095435) Filer
Form 20-F/A
07/20/2026 3:10 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2026 7:11 PM
Portage Biotech (1095435) Filer
Form 20-F
Registration statement / Annual report / Transition report  
07/10/2026 6:51 PM
Portage Biotech (1095435) Subject
Kendall Brazos Duncan (2144955) Filed by
Form SCHEDULE 13G
07/02/2026 4:28 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/16/2026 3:19 PM
Portage Biotech (1095435) Subject
JANE STREET GROUP, LLC (1595888) Filed by
Form SCHEDULE 13G
06/05/2026 12:40 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/04/2026 3:53 PM
Portage Biotech (1095435) Filer
Form 424B3
05/27/2026 11:49 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2026 11:35 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 3:05 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 3:30 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/09/2026 8:07 AM
Portage Biotech (1095435) Issuer
Terpin Michael (1890534) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/07/2026 3:16 PM
Portage Biotech (1095435) Issuer
Villani Fiorenzo (1889272) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/20/2026 4:14 PM
Portage Biotech (1095435) Filer
Form 424B3
02/17/2026 6:51 AM
Portage Biotech (1095435) Filer
Form 424B5
02/17/2026 6:54 AM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2026 3:15 PM
Portage Biotech (1095435) Filer
Form 424B3
01/28/2026 4:23 PM
Portage Biotech (1095435) Filer
Form 424B3
01/28/2026 3:23 PM
Portage Biotech (1095435) Filer
Form 424B3
Top Trader Reveals Stunning Black Friday Deal (Ad)

Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel

Get the Snapback Indicator for just $7 in the Black Friday sale today.
01/28/2026 3:26 PM
Portage Biotech (1095435) Filer
Form 424B3
01/21/2026 5:16 AM
Portage Biotech (1095435) Filer
Form 6-K/A
01/15/2026 3:26 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/15/2026 8:03 AM
Portage Biotech (1095435) Filer
Form 424B5
01/12/2026 7:20 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/31/2025 3:15 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/31/2025 3:16 PM
Portage Biotech (1095435) Filer
Form 424B3
12/31/2025 3:05 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/23/2025 3:05 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/11/2025 11:15 PM
Portage Biotech (1095435) Filer
Form EFFECT
12/09/2025 3:03 PM
Portage Biotech (1095435) Filer
Form 424B3
12/03/2025 4:21 PM
Portage Biotech (1095435) Filer
Form F-3
Registration statement for securities of certain foreign private issuers  
11/25/2025 8:49 PM
Portage Biotech (1095435) Filer
Form 424B5
11/25/2025 8:51 PM
Portage Biotech (1095435) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Portage Biotech SEC Filings - Frequently Asked Questions

Portage Biotech (ALP) has submitted 236+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Portage Biotech's fiscal year ends on March 31. The company typically files its 10-K annual report by the end of May, covering the prior fiscal year's financial results. Key financial data from these reports is available on Portage Biotech's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on November 6, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:ALP are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 11/6/2026. New filings are added as they're published.
From Our Partners